

Supplementary Fig. S5: PCA analysis and significant metabolites of condition media of N9 microglial cells treated with ATP100uM (Negative mode) All the figures in Supplementary Fig.S5 was generated using MetaboAnalyst 5.0 (Version-5.0; URL link: https://www.metaboanalyst.ca/).

Elevated Dimethylarginine, ATP, cytokines, metabolic remodeling involving tryptophan metabolism and potential microglial inflammation characterize Primary Open Angle Glaucoma

- Sujith Kumar Pulukool¹, Sai Krishna Srimadh Bhagavatham¹, Vishnu Kannan^{1,2}, Piruthivi Sukumar³, Rajesh Babu Dandamudi^{4,5}, Shamika Ghaisas⁶, Haripriya Kunchala⁶, Darshan Saieesh¹, Ashwin Ashok Naik¹, Ashish Pargaonkar⁷, Anuj Sharma^{6*}, Venketesh Sivaramakrishnan^{1*}
- ¹ Disease Biology Lab, SSSIHL-Agilent Center for Excellence in Multiomics and Cell Sciences, Dept. of Biosciences, Sri Sathya Sai Institute of Higher Learning, Prasanthi Nilayam, Andhra Pradesh, India, 515 134.
- ² Current address: Dept. of Botany/Biotechnology, CMS College, Kottayam. India 686 001.
- ³ Leeds institute of Cardiovascular and Metabolic medicine, School of medicine, University of Leeds, Leeds, UK
- ⁴ Previous Address: SSSIHL-Agilent Center for Excellence in Multiomics and Cell Science, Dept. of Chemistry, Sri Sathya Sai Institute of Higher Learning, Prasanthi Nilayam, Andhra Pradesh, India, 515 134.
- ⁵ Current address: Phenomenex India, Hyderabad, Telangana, India- 500 084.
- ⁶ Department of Ophthalmology, Sri Sathya Sai Institute of Higher Medical Sciences, Prasanthi Gram, Andhra Pradesh, India, 515 134.
- ⁷ Application Division, Agilent Technologies Ltd., Bengaluru, India.
- *To whom correspondence has to be send: Dr.Venketesh Sivaramakrishnan
- svenketesh@sssihl.edu.in, s.venketesh@gmail.com, and
- Dr. Anuj Sharma <u>anujsharma85@gmail.com</u>
- Venketesh Sivaramakrishnan ORCID- 0000-0003-3094-5905




Supplementary Fig. S5: PCA plot of the control (red color) and condition media of N9 microglial cells treated with ATP100uM (Negative mode)



Supplementary Fig. S5: showing 20 significant differential metabolites in the treated (ATP100 μm) and untreated groups (control) in negative mode

0- Control 1- ATP100uM



Supplementary Fig. S5: showing 20 significant differential metabolites in the treated (ATP100 μm) and untreated groups (control) in negative mode

0- Control 1- ATP100uM